Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Unknown 3Not yet recruiting 3Recruiting 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 2Leukemia, Myeloid, Acute 1Amyloidosis 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Lisaftoclax × Clear all
NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
108 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT04964518 2023-10-25

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
24 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04674514 2023-03-07

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡